openPR Logo
Press release

Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025

01-16-2019 09:46 AM CET | Health & Medicine

Press release from: KuicK Research

Global Bispecific Antibody Market, Drug Sales and Clinical

" Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025" Report Highlights:


Applications of Bispecific Antibodies
Global Bispecific Antibody Market Overview: Drug and Market Sales
Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
US and Japan Market Share Opportunity: andgt;40% by 2025
Bispecific Antibody Clinical Pipeline: 224 Drugs
Commercially Available Bispecific Antibody: 2 (HEMLIBRA and Blincyto)

The research and development of bispecific antibodies has emerged as a new unexplored growth frontier for pharmaceutical industry as per recent research study "Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025" published by Kuick Research. As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets. Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.

The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market. BsAbs due their specificity are gaining a lot of interest from multiple stake holders from the pharmaceutical industry. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Therapeutic antibodies in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of mAbs are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

Currently, there are more than 200 bispecific antibodies in the clinical trials and this number is further expected to increase in coming years driven by research and development and the favorable commercial success to 2 bispecific antibodies available in the market. Most of bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The future for the research and development of bispecific antibodies remains highly progressive and profitable option driven by the fact that increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stake holders of the industry.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-bispecific-antibody-market,-drug-sales--and-clinical-pipeline-insight-2025.php

Report Table of Contents

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removabandreg;)
3.2 Blinatumomab

4. The Design and Engineering of IgG like Bispecific Antibodies
4.1 Quadroma (Hybrid Hydromas) Approach
4.2 “Knobs Into Holes” Approach
4.3 CrossMab Approach
4.4 Dual-Variable-Domain Immunoglobulin Approach

5. The Design and Engineering of Small Bispecific Antibodies
5.1 Bispecific Diabodies
5.2 Bispecific T-Cell Engager Antibodies (BiTEs)

6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

7. Applications of Bispecific Antibodies
7.1 BsMAb for Diagnosis of Infectious Diseases
7.1.1 Diagnosis of Bacterial Infections
7.1.2 Diagnosis of Viral Infections
7.2 BsMAb for Cancer Diagnostic
7.3 BsAbs Blocking Signaling Pathways
7.4 BsAbs Targeting Tumor Angiogenesis
7.5 Specific Delivery of Effector Compounds to Targets
7.6 Bispecific Antibodies and Gene Therapy
8. Global Bispecific Antibody Market Overview
8.1 Current Market Scenario
8.1.1 Catumaxomab (Removab)
8.1.2 Blinatumomab
8.1.3 Duligotumab
8.1.4 SAR 156597
8.2 Global Bispecific Antibodies Clinical Pipeline Overview

9. Global Bispecific Antibody Market Dynamics
9.1 Favorable Market Parameters
9.1.1 Target Patient Base
9.1.2 Severity Of The Disease
9.1.3 Unavailability Of Completely Curing Drugs
9.1.4 Side Effects of the Existing Drugs
9.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells
9.2 Commercialization Challenges
9.2.1 Stringent Regulatory Guidelines
9.2.2 Long Duration of Research and Development
9.2.3 Clinical Trial Timeline
9.2.4 High Cost for Research and Development

10. Global Bispecific Antibody Market Future Prospects

11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-III

12. Marketed Global Bispecific Antibodies Clinical Insight by Company and Indication
12.1 Emicizumab (HEMLIBRA)
12.2 Blinatumomab (Blincyto)

13. No Development Reported and Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Market Withdrawal

14. Competitive Landscape
14.1 Ablynx
14.2 Adimab
14.3 Affimed Therapeutics
14.4 Amgen
14.5 AstraZeneca (MedImmune)
14.6 Chugai Pharmaceutical
14.7 Eli Lilly
14.8 EMD Serono
14.9 Emergent BioSolutions
14.10 Genentech
14.11 Genmab
14.12 Immunomedics
14.13 Jounce Therapeutics
14.14 MacroGenics
14.15 Merus
14.16 Neovii Biotech
14.17 NovImmune SA
14.18 OncoMed Pharmaceuticals
14.19 Pieris
14.20 Regeneron Pharmaceuticals
14.21 Roche
14.22 Sanofi

Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
Figure 3-2: Mechanism of Action of Catumaxomab
Figure 3-3: Mechanism of Action of Blinatumomab
Figure 4-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 4-2: Method of Formation of Hybrid Hybridoma
Figure 4-3: Limitations of Hybrid Hybridoma
Figure 4-4: Steps involved in “Knobs into Holes” Approach
Figure 4-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 4-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 4-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 5-1: Types of Bispecific Antibodies
Figure 6-1: Advantages of Bispecific Antibodies
Figure 7-1: Applications of Bispecific Antibodies
Figure 8-1: BLINCYTO - US v/s Rest of World Sales Share (%), 2017
Figure 8-2: BLINCYTO - US v/s Rest of World Sales Share (%), Q3'2018
Figure 8-3: BLINCYTO - US v/s Rest of World Sales (US$ Million), Q3'2018
Figure 8-4: BLINCYTO - Global Sales (US$ Million), Q1'2018 to Q3'2018
Figure 8-5: BLINCYTO - US and Rest of World Sales (US$ Million), Q1'2018 to Q3'2018
Figure 8-6: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2019 till 2025
Figure 8-7: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2019 till 2025
Figure 8-8: Global - Inactive Bispecific Antibodies in Clinical Pipeline by Phase (%),2019 till 2025
Figure 8-9: Global - Inactive Bispecific Antibodies in Clinical Pipeline by Phase (Numbers), 2019 till 2025
Figure 9-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 9-2: Commercialization Challenges for Bispecific Antibody
Figure 10-1: Japan - HEMLIBRA Market Opportunity For Treatment of Hemophilia A ( US$ Million), 2019 - 2025
Figure 10-2: Global - HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 - 2025
Figure 10-3: USA - HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 - 2025
Figure 10-4: Global - HEMLIBRA Market Opportunity For Treatment of Hemophilia A - Non Inhibitors ( US$ Million), 2019 - 2025
Figure 10-5: USA - HEMLIBRA Market Opportunity For Treatment of Hemophilia A - Non Inhibitors ( US$ Million), 2019 - 2025
Figure 10-6: Global - Bispecific Antibody Market Opportunity ( US$ Billion), 2019 - 2025
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Affimed Therapeutics - Clinical Pipeline
Figure 14-3: Amgen - Clinical Pipeline
Figure 14-4: EMD Serono - Clinical Pipeline
Figure 14-5: Emergent Bioscience - Clinical Pipeline
Figure 14-6: Genmab - Clinical Pipeline
Figure 14-7: Jounce Therapeutics - Clinical Pipeline
Figure 14-8: MacroGenics - Clinical Pipeline
Figure 14-9: Merus - Clinical Pipeline
Figure 14-10: Novimmune - Clinical Pipeline
Figure 14-11: OncoMed - Clinical Pipeline
Figure 14-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 14-13: Roche - Clinical Pipeline






Table 4-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
Table 5-1: List of Bispecific Antibodies Formed by DART
Table 5-2: List of Bispecific Antibodies Formed by BiTE Method
Table 5-3: List of Other BiTEs
Table 7-1: Bispecific Antibodies Targeting Cancer

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025 here

News-ID: 1502435 • Views: 120

More Releases from KuicK Research

Stem Cell Therapy Revolutionizing Conventional Therapy Market
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Download Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportun …
"Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026" Report Highlights: Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 Cell Therapy Clinical Trial Insight by Indication, Company and Country Global Cell Therapy Clinical Pipeline: 767 Cell Therapies Globally Marketed Cell Therapies: 25 Cell Therapies Maximum Number of Marketed Cell Therapies In USA: 15 Therapies Price and Product Insight By Region/Country Regional Analysis of the Cell Therapy Market

All 5 Releases


More Releases for Figure

Figure Skating Equipment Market Report 2018: Segmentation by Type (Figure Skate …
Global Figure Skating Equipment market research report provides company profile for SP-Teri, Graf Skate, Riedell Shoes, Roces, American Athletic, Rollerblade, Winnwell, Dongguan King Line, Jackson Ultima, HD Sports(MK Blades, John Wilson), Edea, Risport Skates, Paramount Skates and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Figure Skating Equipment Sales Market Segmentation and Forecast to 2025
This report studies the global Figure Skating Equipment market status and forecast, categorizes the global Figure Skating Equipment market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). The figure skating equipment includes the Figure Skate Boots, Figure Skate Blades and Figure
Global Leisure Boats Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Leisure Boats Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Leisure Boats in Global market,especially in North America,China,Europe,Southeast Asia,Japan and India,with production,revenue,consumption,import and export in these regions,from 2013 to 2018,and forecast to 2025. This report focuses on top manufacturers in global market,with production,price,revenue and market share for each manufacturer,covering Riva Sunseeker Ferretti Lurssen Azimut Wally Princess Pershing Free Sample of this report is available upon request @
Global Protective Packaging Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Protective Packaging Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Protective Packaging in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and
Global Figure Skating Equipment Market Size,Share : Industry Trends 2022
"The Report Global Figure Skating Equipment Market by Manufacturers, Countries, Type and Application, Forecast to 2022 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" This report studies the figure skating equipment, which includes the Figure Skate Boots, Figure Skate Blades and Figure Skates. Not similar with the common shoes, people should run in and adapt to figure skating equipment, which means they
Long-lasting Performance Improvement with Key Figure Analysis
Vienna/Reutlingen, October 17, 2012 – Manz, a leading high-tech mechanical engineering company, is optimizing its processes in strategic sourcing in order to recognize the risks and potential associated with each supplier early on so that the sourcing department can react to them in time. POOL4TOOL’s customized eSolutions localize and analyze key figures that are relevant to the decision making process, and displays these figures in a comprehensive and transparent way.